ArticleDermatology online journal2025
Corticosteroid-induced central serous chorioretinopathy in a pemphigus vulgaris patient.
Article in Dermatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corticosteroids are effective and relatively inexpensive medications used worldwide for multiple inflammatory diseases. Their use is marred by several well-established side effects, including hyperglycemia, weight gain, osteoporosis, monomorphic corticosteroid-induced acne, gastrointestinal disturbances, cataract, and glaucoma. We report a 29-year-old man with pemphigus vulgaris who achieved disease control with high-dose oral prednisolone and mycophenolate mofetil. While on treatment, he developed blurring of vision from 1 eye and was found to have central serous chorioretinopathy (CSCR). The condition was attributed to high-dose corticosteroid use by the ophthalmologist, who advised discontinuation of the offending drug as soon as possible. A rapid taper of corticosteroids was initiated to preserve vision while maintaining disease control. To our knowledge, CSCR has not been previously described in a patient with pemphigus vulgaris or other cutaneous immunobullous disorders in the English medical literature. This case aims to raise awareness of this rare ocular complication, which, if left untreated, can result in permanent vision loss.
Indexed as
Identifiers
41725474What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.